Outcomes of advanced soft tissue sarcoma from dedicated medical oncology sarcoma clinic in North India and evaluation of the respective model.

Rastogi, Sameer; Sharma, Atul; Aggarwal, Aditi; Naresh, G.; Barwad, Adarsh; Dhamija, Ekta; Panday, Rambha

doi:10.1200/jco.2018.36.15_suppl.e23561

Cited by 1 publication

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As per cancer statistics in the United States, the incidence of STSs is approximately 0.72%, 1 whereas incidence data on STSs in India are unknown as studies in published literature are limited to the retrospective institutional case series. [9][10][11][12] STS incidence increases with age, with the reported median age in Western literature falling in the sixth decade. [16][17][18] In our study, the median age was 45 years, which was comparable to that of other studies from different parts of India, as shown in ►Table 2.…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, Rastogi et al reported extremity followed by retroperitoneum as the most frequent sites. 12 Being a rare tumor with more than 50 subtypes makes histopathological subtyping difficult. STSs are often labeled high-grade sarcomas or undifferentiated pleomorphic sarcomas when specific lines of differentiation are not identified.…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, most Indian studies reported synovial sarcoma as the most common histopathological type, as shown in ►Table 2. 9,10,12 However, with standardization of diagnostic criteria and extended immunohistochemistry, some of the undifferentiated pleomorphic sarcomas can be reclassified into specific subtypes. 24 Furthermore, translocation studies may sort out a few discrepancies, as shown in the GENSARC study.…”

Section: Discussionmentioning

confidence: 99%

“…A retrospective analysis of 156 advanced STS patients from North India reported a median OS of 16 months. 12 Another study from the United States of 363 metastatic STS patients reported a median OS of 22 months and 17 months among treated and untreated patients, respectively. 18 The basis of a good outcome in our metastatic patients may be a result of improved outcomes in 25% of these patients who underwent complete resection.…”

Section: Discussionmentioning

confidence: 99%

“…There is a paucity of prospective studies in STS from the Indian subcontinent and low-to-middle-income countries, as most of the previous studies in the published literature are retrospective case series. [9][10][11][12] The present study was done prospectively to gain insight into the disease patterns and outcomes of STS in the Indian setup. Understanding STS patients' profile is essential in improving care for sarcoma patients and also for further research, to emphasize the significance of multidisciplinary management, and to raise awareness about the importance of STS collaborative network group in India.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Adult Soft Tissue Sarcoma: A Prospective Observational Real-World Data

Shivarudraiah

Sundaram

Suresh

et al. 2021

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Introduction There is a lacuna of prospective studies on soft tissue sarcoma (STS) from the Indian subcontinent in published literature. Objectives We conducted this study to describe the clinical profile and outcomes of STS in North India. Materials and Methods This is a single-center, prospective, observational study conducted from October 2017 to September 2019. All consecutive patients aged ≥18 years with histopathological diagnosis of STS were enrolled. The study end points included overall response rate, progression-free survival (PFS), and overall survival (OS). Results A total of 140 patients were included with a median duration of follow-up of 14 months (range: 1–25 months). The median age of patients was 45 years. The median duration of symptoms before diagnosis was 5 months (range: 1–18 months). The most common histopathologic subtype was undifferentiated pleomorphic STS (22%). Of 105 localized patients, 21 received neoadjuvant therapy with external beam radiotherapy and/or doxorubicin-based chemotherapy and reported partial response in 38% (8/21) of the patients; the remaining 62% (13/21) of the patients had stable disease. Neoadjuvant therapy resulted in nonsignificantly higher complete resection rates with relative risk of 2.37 (p = 0.19). Of the remaining 35 metastatic STS patients, 31 received chemotherapy and reported partial response in 39.1% (n = 9/23), stable disease in 30.4% (n = 7/23), and disease progression in 30.4% (n = 7/23) of the patients. For localized STS patients, 1-year disease-free survival (DFS) and OS rates were 87.6 ±3.5 and 95.3 ± 2.3%, respectively. The median OS for metastatic STS patients was 23.90 months (95% confidence interval [CI]: 7.43–40.36). Among metastatic STS, median OS was not reached for those who underwent curative resection versus 12.66 months (95% CI: 9.28–16.04) for those who received systemic therapy alone. Conclusion Median age of 45 years is a decade earlier than seen in the Western population. Neoadjuvant therapy improved complete resection rates, though it was statistically nonsignificant. Curative resection among metastatic STS patients improves survival.

show abstract